Skip to content

Released Mar 10, 2022, before the open

10-K filed Mar 10, 2022, 69 days after period end · 0001628280-22-005753

Q4 2021 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$713.00Kderived+184.1% vs Q4 2020+1,639.0% vs Q3 2021
Net Income-$29.14MderivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$28,082,000N/M
Operating Cash Flowderived$11,882,000N/M
Free Cash Flowderived$11,802,000N/M
Margins · derived
Operating margin-3938.6%+4339.9 pt vs Q4 2020
Net margin-4087.4%+4182.7 pt vs Q4 2020

What the release said

The release

Same quarter

MetricQ4 2021derived from reported figuresQ4 2020derived from reported figuresQ4 2019derived from reported figures
Revenue$713.00K$251.00K—
Net Income-$29.14M-$20.76M—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR